Назад

Personalized treatment COVID-19

Oncogene and Alfa Diagnostica announce the launch of a new technology that allows the evaluation of the safety and efficacy of COVID-19 subsequent treatment.

In the context of the pandemic, the selection of the optimal strategy for an efficient and safe treatment of patients with COVID-19 becomes extremely topical. Current treatment protocols include medicinal products that demonstrate the best therapeutic potential: chloroquine (Chloroquine), hydroxychloroquine (Hydroxychlorochinum), anakinra (Anakinrum) and lopinavir + ritonavir (Lopinavir + Ritonavir), individual efficacy and tolerability vary.

In order to adjust the doses and predict the safety of treatment with these preparations, a special pharmacogenetic panel was developed that analyzes the genetic markers, determines their metabolism or pharmacokinetics. The panel also analyzes other markers: G6PD (increased risk of neonatal hyperbilirubinemia, hemolytic anemia and recurrent infections); SLCO1B1 (increased risk of adverse reactions to Lopinavir); Interleukin-1 (increased risk of side effects Anakinra).

indications

Clinical decision support in the process of choosing the potentially effective and safe treatment for COVID-19. Technology Stage I – complete exomic sequencing of the patient’s DNA (> 20,000 genes) *. Stage II – analysis of pharmacogenomic data. Stage III – medical report. The genomic data obtained can be used in the future to identify tumor markers, in addition to the tumor model, FFPE.

Testing

The signing of the contract and the payment of the test takes place in the office of the company ONCOGENE, the blood collection for testing takes place in the medical laboratory Alfa Diagnostica.Terms and preparation not required) .About ONCOGENE SRLCompany that owns and operates the ONCOGENE® service, specializing in genomic profiling and tumor interpretation.Official website: www.oncogene.euE-mail: client-support@oncogene.eu For testing questions, call: + 373 22 81 90 90 or 068 28 77 28